- 1 Genomic epidemiology of the rotavirus G2P[4] strains in coastal Kenya pre- and post-
- 2 rotavirus vaccine introduction, 2012 2018
- 3

4	Timothy O. Makori <sup>1, 2</sup> , Joel L. Bargul <sup>2, 3</sup> , Arnold W. Lambisia <sup>1</sup> , Mike J. Mwanga <sup>1</sup> , Nickso	n						
5	Murunga <sup>1</sup> , Zaydah R. de Laurent <sup>1</sup> , Clement S. Lewa <sup>1</sup> , Martin Mutunga <sup>1</sup> , Paul Kellam <sup>4, 5</sup> ,							
6	Matthew Cotten <sup>6,7</sup> , D. James Nokes <sup>1,8</sup> , My Phan <sup>6,7,*</sup> , and Charles N. Agoti <sup>1,9,*</sup>							
7								
8	Affiliations:							
9	1. Kenya Medical Research Institute (KEMRI)-wellcome Trust Research Programme	е,						
10	off Hospital Road, Kilifi 80108, Kenya; tmakori@kemri-wellcome.org (T.O.M.	);						
11	ALambisia@kemri-wellcome.org (A.W.L.); jmwanga@kemri-wellcome.or	g						
12	(M.J.M.); nmurunga@kemri-wellcome.org (N.M.); zdelaurent@gmail.com	m						
13	(Z.R.d.L.); CLewa@kemri-wellcome.org (C.L.); MMutunga@kemri-wellcome.or	g						
14	(M.M.); jnokes@kemri-wellcome.org (D.J.N.); cnyaigoti@kemri-wellcome.or	g						
15	(C.N.A.).							
16	2. Department of Biochemistry, Jomo Kenyatta University of Agriculture an	ıd						
17	Technology, Juja 62000-00200, Kenya; Jbargul@jkuat.ac.ke (J.L.B).							
18	3. International Centre of Insect Physiology and Ecology, Animal Health Theme, P.C.	).						
19	Box 30772-00100, Nairobi, Kenya; jbargul@icipe.org (J.L.B).							
20	4. Department of Infectious Diseases, Fulculty of Medicine, Imperial College London	n,						
21	London, UK; p.kellam@imperial.ac.uk (P.K)							
22	5. Kymab Ltd, The Bennet Building (B930), Babraham Research Campus, Cambridge	e,						
23	UK							
24	6. Medical Research Centre (MRC)/ Uganda Virus Research Institute, Entebbe, Uganda	ì						
25	7. MRC-University of Glasgow, Centre for Virus Research Glasgow, United Kingdon	n;						
26	Matthew.Cotten@lshtm.ac.uk (M.C.); My.Phan@lshtm.ac.uk (MP).							
27	8. School of Life Sciences and Zeeman Institute (SBIDER), The University of Warwich	k,						
28	Coventry CV4 7AL, UK							
29	9. School of Health and Human Sciences, Pwani University, Kilifi 80108, Kenya							
30								
31	Keywords:							
32	Rotavirus group A, G2P[4], Coastal Kenya							
33								

34

### 35 ABSTRACT

36 The introduction of rotavirus vaccines into the national immunization programme in many 37 countries has led to a decline of childhood diarrhoea disease burden. Coincidentally, the 38 incidence of some rotavirus group A (RVA) genotypes, has increased, which may result from 39 non-vaccine-type replacement. Here we investigate the evolutionary genomics of rotavirus 40 G2P[4] which has shown an increase in countries that introduced the monovalent Rotarix® 41 vaccine. We examined the 63 RVA G2P[4] strains sampled from children (aged below 13 42 years) admitted to Kilifi County Hospital, Coastal Kenya, pre- (2012 to June 2014) and post-43 (July 2014-2018) rotavirus vaccine introduction. All the 63 genome sequences showed a 44 typical DS-1 like genome constellation G2-P[4]-I2-R2-C2-M2-A2-N2-T2-E2-H2. G2 sub-45 lineage IVa-3 strains predominated in the pre-vaccine era co-circulating with low numbers of 46 G2 sub-lineage IVa-1 strains, whereas sub-lineage IVa-3 strains dominated the post-vaccine 47 period. In addition, in the pre-vaccine period, P[4] sub-lineage IVa strains co-circulated with 48 low numbers of P[4] lineage II strains, but P[4] sub-lineage IVa strains predominated in the 49 post-vaccine period. On the global phylogeny, the Kenyan pre- and post-vaccine G2P[4] 50 strains clustered separately, suggesting that different virus populations circulated in the two 51 periods. However, the strains from both periods exhibited conserved amino acid changes in 52 the known antigenic epitopes, suggesting that replacement of the predominant G2P[4] cluster 53 was unlikely a result of immune escape. Our findings demonstrate that the pre- and post-54 vaccine G2P[4] strains circulating in Kilifi, coastal Kenya, differed genetically, but likely 55 were antigenically similar. This information informs the discussion on the consequences of 56 rotavirus vaccination on rotavirus diversity.

57

58

### 59 INTRODUCTION

60 In 2009, the World Health Organization (WHO) recommended inclusion of rotavirus 61 vaccines into the national immunization programmes (NIPs) globally [1]. Kenya introduced 62 the WHO pre-qualified Rotarix® RVA (rotavirus group A) vaccine into its NIP in July 2014 63 [2]. With the increasing uptake of rotavirus vaccines globally, there has been a significant 64 reduction in RVA-associated disease burden, but this virus still caused about 128,500 deaths 65 in 2016 alone [3,4], with the majority of cases occurring in low-income countries [5]. In 66 Kenya, post-vaccine introduction impact studies have reported significant reduction of 67 rotavirus-associated diarrhoea hospitalization in children under five years, a vaccine 68 effectiveness of ~64% [6], and a significant increase in the positivity rate of Rotarix® 69 heterotypic genotypes such as G2P[4] and G3P[8] [7,8]. Similar findings were observed in 70 other countries that introduced the Rotarix® vaccine in their NIPs [9–18]

71 Whole genome analysis of RVA can reveal the transmission and evolutionary history of 72 circulating strains, including emerging mutations, and the origins and genetic diversity of the 73 strains circulating in a particular region [19]. The rotavirus G2P[4] genotype is known to 74 possess a DS-1 like genomic constellation (G2-P[4]-I2-R2-C2-M2-A2-N2-T2-E2-H2) [20]. 75 G2P[4] strains are believed to have undergone genetic evolution in a stepwise pattern [21]. 76 This is from lineage I to IVa in the NSP5, NSP1, VP2, VP4, and VP7 genome segments, and 77 from lineage I to V in the VP1, VP3, VP6, NSP2, NSP3, and NSP4 genome segments, with 78 some of the strains undergoing intragenotype reassortments in the VP7, VP3, and NSP4 79 genes after 2004 giving rise to emergent lineages of V in the VP7 segment, lineages VI and 80 VII in the VP3 gene, and VI, VII, VIII, IX and X lineages in the NSP4 gene [21–23]. The 81 G2P[4] lineages circulating in Kenya are unknown.

82 Characterization of South African G2P[4] strains, through comparison of strains 83 occurring during pre-and post-introduction of Rotarix® vaccine, revealed sub-lineage shifts 84 from G2 sub-lineage IVa-1 to G2 IVa-3, and P[4] sub-lineage IVa to P[4] IVb, and these 85 shifts in genetic evolution were attributed to arise due to natural fluctuations and not as a 86 result of vaccine pressure [24]. Similarly, G2P[4] whole genome analysis in Ghana [22], 87 Australia [25,26], South Korea [11], Bangladesh [27], and Brazil [28] showed that 88 implementation of Rotarix® vaccination does not influence genetic diversity of the 89 circulating G2P[4] strains and common amino acid replacements in the VP7 antigenic 90 epitopes including A87T, D96N, S213D were reported, irrespective of the vaccination period.

The main goal of this study was to conduct whole genome analysis of the G2P[4] genotypes circulating in Kilifi County, Kenya, to determine whether introduction of Rotarix® vaccine in Kenya's NIP impacts on the genetic diversity of the circulating G2P[4] viral populations. Data from this study were compared with contemporaneous global RVA strains to establish the phylogenetic context and potential origin of the Kenya's pre- and postvaccination rotavirus G2P[4] strains.

## 97 MATERIALS AND METHODS

## 98 Ethical approval

99 We collected samples from children to screen for and determine the genetic diversity of 100 rotavirus group A (RVA) viral populations. The study was conducted with strict adherence to 101 the study protocols approved by the Scientific and Ethics Review Unit (REF: #3049 and 102 #2861) at the Kenya Medical Research Institute, KEMRI, Nairobi, Kenya. Parents and 103 guardians of the eligible children were provided with sufficient information about the 104 research study to allow each individual to make informed and independent decisions for their 105 children to be enrolled in the study. Sample collection proceeded after obtaining written 106 informed consent from the parents and guardians.

## 107 Study participants

The study was based at Kilifi County Hospital (KCH), a referral health facility that mainly serves the people of Kilifi County located in the North Coast of Kenya [29]. Stool samples were obtained from children, aged below 13 years, who presented with diarrhoea as one of the illness symptoms and were admitted at KCH [6,30]. Diarrhoea was defined as passing of watery stool at least three times in the last 24 hours.

The stool samples were screened to detect RVA by using ELISA kit (ProSPect<sup>™</sup>; Oxoid, Basingstoke UK). All the RVA positive samples were initially genotyped by partial segment sequencing approach [7]. VP7 and VP4 genes were sequenced, and G and P genotypes inferred using the Virus Pathogen Resource (VIPR) tool for RVA [31]. Those classified as G2P[4] based on the outer capsid proteins were selected for this study (Fig. 1) [7].

# 118 RNA extraction and processing

119 The samples collected in the pre-vaccine period (January 2012 – June 2014) were 120 sequenced using agnostic whole genome sequencing method [32], while the post-vaccine

samples (July 2014 – December 2018) were sequenced using an amplicon-based whole
genome sequencing approach [33,34].

123 Processing of pre-vaccine samples was done by centrifugation of 110 µL of stool 124 suspension in PBS (phosphate buffered saline) for 10 minutes at  $10,000 \times g$ . Next, 2 U/µl of 125 TURBO DNase (#AM2238; Life Technologies, Carlsbad, USA) were added to degrade non-126 encapsulated DNA. Nucleic acid extraction was performed according to the Boom method 127 [35]. First strand cDNA was synthesized using the SuperScript III Reverse Transcriptase Kit 128 (#18064014; Life Technologies, Carlsbad, USA) with non-ribosomal random hexamer 129 primers [36]. Second strand cDNA was synthesized using 5U of Klenow fragment 3' - 5'130 exo- (#M0212S; New England Biolabs, Ipswich, USA).

131 Processing of post-vaccine introduction samples was done by subjecting 200 mg of stool 132 specimens to bead beating [37], followed by nucleic acid extraction using the QIA amp Fast 133 DNA Stool Mini kit (#51604; Qiagen, Manchester, UK) following the manufacturer's 134 instructions. Reverse Transcription-PCR (RT-PCR) was performed using the SuperScript IV 135 One-Step RT-PCR System (#2594025, Thermo Fisher Scientific, Waltham, USA) following 136 the manufacturer's instructions. The published primers used in our study to conduct RT-PCR 137 assays were adopted from earlier studies (Table S1) [33,34]. The PCR conditions for the non-138 structural gene segments (NSP1, NSP2, NSP3, NSP4, and NSP5) consisted of 40 cycles of 139 thermocycling (30 seconds at 90°C, one minute at 55°C, and four minutes at 68°C), whereas 140 amplification of structural gene segments (VP1, VP2, VP3, VP4, VP6, and VP7) included 40 141 cycles of thermocycling (90°C for 30 seconds, 61°C for one minute and 68°C for six 142 minutes), and included a final extension at 72°C for four minutes. PCR amplicons were 143 resolved under a 2% agarose gel stained with RedSafe (iNtRON Biotechnology, Inc) for 144 visualization of DNA bands. PCR products were purified using Exonuclease I (#EN0581; 145 Thermo Fisher Scientific, Waltham, USA) as described by the manufacturer and pooled for 146 each sample.

## 147 *Next generation sequencing*

Preparation of standard Illumina libraries for pre-vaccine samples was performed according to the published protocol [32]. Briefly, the double-stranded cDNA for each sample was sheared to obtain 400 – 500 nucleotide fragments. Each sample was then indexed separately to unique adapters and multiplexed at 95 samples and then sequenced on a HiSeq platform to generate about 1.5 million 250bp paired end reads per sample.

153 For the post-vaccine samples was done by purifying the pooled amplicons for each sample 154 using the Agencourt AMPure XP Kit (#A63881; Beckman Coulter, USA) as described by the 155 manufacturer. Library preparation was performed using the Illumina DNA flex (#20025519, 156 Illumina, San Diego, USA) as per the manufacturer's specifications. Briefly, bead-linked 157 transposomes were used to tagment the DNA, followed by addition of adapters to the DNA 158 fragments using a limited PCR program. The adapter-linked DNA was cleaned using the 159 tagment wash buffer. After that, the purified tagmented DNA was amplified via a limited-160 cycle PCR program that adds the i7, i5 adapters and sequences required for cluster generation 161 during sequencing. Next, the amplified libraries were purified using a double-sided bead 162 purification method. Subsequently, each DNA library was quantitated, and correct insert sizes 163 confirmed on an Agilent 2100 Bioanalyzer using the Agilent high sensitivity DNA kit 164 (#5067; Agilent, Santa Clara, USA). The DNA libraries were quantified on the Qubit 165 fluorimeter 2.0 using the Qubit dsDNA HS Assay kit (#Q32851, Life Technologies, Thermo 166 Fisher Scientific, Waltham, USA), normalized, and pooled at equimolar concentrations. 167 Pooled DNA libraries were denatured and sequenced on the Illumina MiSeq platform 168 (Illumina, San Diego, USA) to generate 150 paired end reads.

#### 169 *Genome assembly*

170 Quality trimming of Illumina FASTQ reads was done using Trimmomatic (Phred score 171 >30) with the following flags "ILLUMINACLIP: adapters file: 2:30:10 LEADING:3 172 TRAILING:3 SLIDINGWINDOW: 4:15 MINLEN:36" to remove adapters and low-quality 173 bases [38]. De-Novo assembly of the quality trimmed reads was done using Spades with the 174 following flags "-k 99,127 --careful" [39]. For the pre-vaccine sequences, RVA-specific 175 contigs were identified using USEARCH [40] and a SLIM algorithm [41]. Partial and 176 overlapping contigs were joined using Sequencher [42] to obtain full-length sequences. For 177 the post-vaccine sequences, Quast was used to check the quality of the contigs [43]. Next, 178 artemis was employed to determine the ORFs of each RVA segment [44]. Then, genotyping 179 of the assembled pre- and post-vaccine sequences was done using the Virus Pathogen 180 Resource tool for RVA [31]. The nucleotide sequences generated in this study have been 181 deposited into GenBank under accession numbers MZ093788 to MZ097268 and OP677569 182 to OP677754 (Table S2).

### 183 *Global sequences collection and processing*

All available G2P[4] sequences irrespective of the sequence length and their corresponding metadata, including year of collection and location were downloaded from the Virus Pathogen Resource of RVA [31]. Records missing metadata were manually searched

187 and any information, including location and collection year, that could be found in the 188 primary publications was included in the respective sequence data. The sequences were 189 subset to obtain datasets of each genome segment. The datasets of all the genome segments 190 were filtered to only include samples with all the 11 segments. For all the 11 segments, more 191 that 80 % of the coding sequence (CDS) region was considered for analysis. Overall, 350 192 global sequences for each segment met the inclusion criteria for phylogenetic analyses (Table 193 S2).

## 194 Phylogenetic analysis

195 The global dataset was combined with the sequences of this study for each genome 196 segment and aligned using MAFFT (v7.487) with the command "mafft --auto --reorder --197 preservecase input\_file.fasta > output\_file.fasta" [45]. Maximum likelihood phylogenetic 198 trees were reconstructed using IQTREE2 (v2.1.3) [46] using the best model selection [47] 199 and 1000 bootstrap replication settings [48]. The ML trees were linked to the respective 200 metadata in R v4.1.0 and the "ggTree" R package used to plot and visualize the trees [45]. 201 For lineage designation, sequences of previously described lineages for each segment [21–23] 202 were utilized as the references (Table S2).

# 203 *Statistical analyses*

All statistical analyses were carried out using Stata v13.1 [49]. Chi-square test was used to compare among groups, with P< 0.05 indicating statistical significance.

### 206 RESULTS

# 207 Baseline characteristics of the study participants

Peaks of rotavirus A (RVA) infections coincided with cases of diarrhoea during the study period between May and September (Fig. 1). However, sample collection was majorly disrupted in 2016 and 2017 by strikes of health care providers (Fig. 1) [6]. One huge peak of G2P[4] infections was observed between June and November 2016 (post-vaccine) and a small one documented between May and September 2012 (pre-vaccine) (Fig. 1).

No significant difference was reported in age, age groups, gender, and vaccination status between the cases infected with G2P[4] genotypes and the non-G2P[4] genotypes (P>0.05) (Table 1). G2P[4] genotypes were detected in 87 samples (20.3%), of which 63 (14.7%) were successfully full-genome sequenced (Table 1). Of the sequenced samples, 13 (20.6%) were from children who received two doses of the Rotarix® vaccine (Table 1).

## 218 Genome constellations

To determine the genetic diversity in the Kilifi G2P[4] strains and their genetic relatedness with global strains, near full-genome sequences (>80% genome coverage) of 63 Kilifi samples were sequenced from the pre- (n=33) and the post- (n=30) vaccine periods (Table S2). Using the Virus Pathogen Resource (VIPR) for RVA genotype determination [31], all the 63 sequences were classified as G2-P[4]-I2-R2-C2-M1-A2-N2-T2-E2-H1 genotype (DS-1-like typical genome constellation) as shown in Table S3.

# 225 Phylogenetic and sequence analysis

To gain insights into the genetic diversity of the study G2P[4] strains in the global context, genetic distance-resolved phylogenetic trees were constructed for all the 11 gene segments (Fig. 2 & Fig. S1). Sequence identity matrices of the study G2P[4] strains exhibited high nucleotide sequence similarities (93 – 100%) in the NSP1, NSP2, NSP3, NSP5, VP1, VP2, VP4, VP6, and VP7 genome segments, and low to high nucleotide sequence similarity (85 – 100%) in the VP3 and NSP4 genes (Table 2).

## 232 Analysis of the VP7 gene

233 The VP7 gene is highly variable and encodes the humoral immune response glycoprotein 234 [50]. The VP7 genetic distance-resolved phylogenetic tree showed that the Kilifi sequences 235 formed three clusters: a monophyletic cluster, a minor monophyletic cluster, and a singleton 236 (Fig. 2). Within the major cluster, the Kilifi strains separated by vaccination period, with one 237 subcluster consisting of strains circulating two years after Rotarix® vaccine introduction and 238 were interspersed with three strains isolated from children admitted to Kenyatta National 239 Hospital (KNH), Kenya in 2017 (Fig. 2). These sequences shared two non-synonymous 240 amino acid substitutions (S72G, S75L) with respect to the pre-vaccine strains (Table S4). The 241 second subcluster mainly consisted of strains circulating in the pre-vaccine period and two 242 strains that circulated in July 2014, i.e., early post-vaccine period (Fig. 2). The sequences in 243 the minor monophyletic cluster consisted of five Kilifi strains collected in 2012, while the 244 singleton Kilifi strain (KLF1033/2018) clustered with three strains detected in Mozambique 245 in 2013 (Fig. 2).

With regards to the VP7 lineages, the Kilifi G2 strains were classified into lineage IV and further classified into sub-lineage IVa-1 and IVa-3 (Fig. 2). In 2012, sub-lineages IVa-1 and IVa-3 sequences co-circulated in Kilifi, while in the global context sub-lineages IVa-1, IVa-3 and IV non-a co-circulated (Fig. 3A). However, IVa-1 strains in Kilifi were replaced with sub-lineage IVa-3 strains in 2013 that dominated until 2018 (Fig. 3A), unlike in the global

251 context where sub-lineages IVa-1, IVa-3 and V co-circulated in 2013, sub-lineage IVa-1

252 predominantly circulated in 2014, IVa-1 and V co-circulated in 2015, and IVa-3 re-emerged

- in 2016 replacing lineage V and co-circulated with sub-lineage IVa-1 until 2018 (Fig. 3A).
- 254 No lineage shift was observed pre- and post-vaccine introduction.
- 255 Analysis of the VP4 gene

256 The VP4 gene is highly variable and encodes a highly immunogenic protease sensitive 257 protein involved in receptor binding and cell penetration [50]. In the VP4 phylogenetic tree, 258 the P[4] Kilifi sequences formed clusters (n>2) mainly based on the vaccination period 259 separated from global sequences (Fig. 2). However, two Kilifi sequences formed singletons, 260 with the KLF1033/2018 strain clustering with a sequence isolated from a child admitted to 261 KNH, while the KLF0616/2012 strain was interspersed with sequences from Mozambique 262 (Fig. 2). A major cluster of Kilifi sequences further sub-clustered based on the vaccination 263 period, with the post-vaccine sequences interspersing with Kenyan sequences isolated from 264 children admitted to KNH (Fig. 2). In addition, Kilifi strains collected in 2014 and some 2012 265 strains formed two distinct clades, clustering separately from global sequences (Fig. 2).

During the study period, G2 lineages II and IVa strains circulated in Kilifi, with lineages II and IV co-circulating in 2012, consistent with the global context (Fig. 3B). From 2013 to 2018, sub-lineage IVa predominantly circulated in Kilifi similar the global context (Fig. 3B). However, in the global context, few lineage II strains co-circulated with IVa strains in 2017 (Fig. 3B). No lineage shift was observed pre- and post-vaccine introduction (Fig 2).

### 271 Analysis of the backbone genome segments

272 The backbone genome segments of the Kilifi G2P[4] strains (VP6, VP1-VP3, and NSP1-273 NSP5) formed up to four clusters on the global phylogenetic trees (Fig.S1). In the VP6, VP1, 274 VP2, VP3, NSP1, and NSP2 genes, majority of the Kilifi sequences formed one major cluster 275 which further separated into two sub-clusters of only pre- and post-vaccine sequences (Fig. 276 S1). The post-vaccine strains in these genes clustered closely with 2017 sequences from 277 KNH, Kenya (Fig.S1). In addition, the Kilifi 2014 sequences in the VP6, VP3, NSP1, and 278 NSP2 segments exhibited a different clustering pattern of a further minor sub-cluster 279 irrespective of the vaccination period, consistent with the VP4 gene (Fig. S1). Four post-280 vaccine sequences were interspersed with the pre-vaccine sequences in the NSP4 gene and a 281 singleton of post-vaccine sequence clustered with pre-vaccine sequences in the NSP3 gene 282 (Fig. S1). The NSP5 post-vaccine sequences formed one cluster, while the pre-vaccine

283 sequences exhibited a different clustering pattern consisting of three distinct clusters ( $n\geq 2$ ) 284 and three singletons (KLF0601/2012 was interspersed with a sequence from KNH, 285 KLF1066/2014 and KLF0722/2014) (Fig. S1). A minor cluster consisting of five Kilifi pre-286 vaccine strains (KLF0550/2012, KLF0551/2012, KLF0553/2012, KLF0558/2012, and 287 KLF1064/2012) separate from global sequences was observed in the VP1, VP2, VP3, NSP2, 288 NSP4, and NSP5 genes; however, interspersed with sequences that circulated between 2012 289 and 2017 in Japan, Hungary, Australia, and Belgium in the NSP3 gene and further formed 290 two sub-clades in the VP6 gene (Fig. S1). In addition, a minor cluster of Kilifi pre-vaccine 291 sequences (KLF0640/2013, KLF0673/2013, and KLF0657/2013) interspersed with sequences 292 from Malawi was observed in the VP3 gene, indicating possible importation of these strains 293 (Fig. S1). Besides, a singleton of a post-vaccine sequence (KLF1033/2018) was interspersed 294 with sequences from Mozambique that circulated in 2013 across all the backbone genes (Fig. 295 S1). For the NSP5 gene, three other singletons were observed: KLF0601/2012 interspersed 296 with a sequence from KNH, KLF1066/2014 and KLF0722/2014 each separate from global 297 sequences (Fig. S1). No lineage shifts were reported in the backbone genome segments (Fig. 298 S1).

# 299 Amino acid changes in the VP7 glycoprotein (G) and VP4 Protease sensitive (P) proteins

300 The pattern of amino acid (aa) substitutions in the G and P proteins was analysed in 301 relation to the ancestral DS-1 sequence. The VP7 gene contains 7-1 (7-1a and 7-1b) and 7-2 302 antigenic epitopes, which affect the ability of antibodies to neutralize virus infectivity and 303 reduce vaccine effectiveness [51]. The Kilifi strains exhibited 17 aa changes relative to the 304 DS-1 VP7 ancestral sequence (Table S4). All the Kilifi strains had three aa mutations (D96N, 305 N125T, and V129M) in the 7-1a antigenic epitope with respect to the DS-1 ancestral strain 306 (Fig. 4 & Table S4). Furthermore, except for the 2014 sequences, the Kilifi sequences 307 exhibited an A87T aa mutation in the 7-1a epitope (Table S4). Compared to the DS-1 308 sequence, the Kilifi sub-lineage IVa-1 strains exhibited the N242 aa mutation, whereas sub-309 lineage IVa-3 strains harboured the N213D aa mutation; both in the 71-b epitope. (Table S4). 310 Besides, the I44M as change was observed in the T lymphocyte epitope (40 - 52) of all the 311 Kilifi strains (Table S4).

The VP4 surface protein is cleaved into the VP8\* and the VP5\* domains containing the 8-1 to 8-4 and 5-1 to 5-5 antigenic epitopes [52]. Analysis of the VP4 aa mutations revealed that the Kilifi strains differed only at three positions; Q114P or L114P and N133S in the 8-3

epitope and N89D in the 8-4 epitope, relative to the DS-1 prototype sequence (Fig 4 & TableS5).

#### 317 DISCUSSION

We investigated the evolutionary dynamics of G2P[4] strains sampled from children admitted to Kilifi County Hospital, Coastal Kenya between 2012 and 2018. All the recovered genomes showed a typical DS-1 like constellation consistent with findings from several countries using the Rotarix® vaccine in their NIPs [21,22,24,53].

322 Separate clusters of pre- and post-vaccine sequences were observed in the VP1-VP4, VP6, 323 VP7, NSP1, NSP2, and NSP5 segments. However, the strains sampled in July 2014 (early 324 post-vaccine period) clustered with pre-vaccine strains across all the 11 gene segments in our 325 study possibly because the vaccine coverage was low and thus had no impact yet on the 326 circulating genotypes and lineages. Unique clusters of either G2P[4] or G1[P8] strains 327 separated by RVA vaccine period have been reported in South Africa [24], Rwanda [54], 328 Australia and Belgium [55], which were interpreting as reflecting natural genetic fluctuations 329 rather than vaccine induced evolution. However, the study NSP4 and NSP3 genes exhibited 330 some clusters of mixed pre- and post-vaccine sequences, indicating that in some strains the 331 pre-vaccine may have reassorted with post-vaccine introduction strains as similarly suspected 332 in Mozambique, albeit in G1P[8] [56].

333 Phylogenetic analyses indicated that the diversity of the Kilifi G2P[4] strains may have 334 been locally restricted both in the pre- and post-vaccine periods, since Kilifi sequences 335 clustered away from global sequences in all the 11 genome segments. In addition, limited 336 sequence data from Kenya and East Africa may have contributed to this uncertainty about the 337 regional context of Kilifi diversity. The Kilifi post-vaccine strains only clustered with 338 Kenyan sequences sampled from children admitted to Kenyatta National Hospital in 2017, 339 further suggesting locally restricted genetic evolution. However, one sample 340 (KLF1033/2018) consistently clustered with sequences from Mozambique and some pre-341 vaccine strains were interspersed with global strains for the NSP3 segment, suggestive of 342 limited introduction from other countries. No lineage shift was observed pre- and post-343 periods in Kilifi inconsistent with findings in South Africa [24] where RVA vaccine 344 introduction resulted in lineage shift. Furthermore, few G2 and P[4] lineages were in 345 circulation within Kilifi compared with the combined global data during the study period.

This supported our hypothesis that local drivers were responsible for the diversity within theKilifi setting.

348 The Kilifi strains harbored six conserved amino acid (aa) substitutions in the VP7 349 antigenic epitopes; 7-1a and 7-1b with respect to the ancestral DS-1 G2P[4] strain. Three of 350 these positions (A87T, D96N, and N213D) are critical for antibody binding and sequence 351 changes here may lead to escape from host neutralizing antibodies [57]. The I44M aa change 352 may affect cellular immunity as this region harbors a known T lymphocyte epitope (40-52) of 353 the VP7 genes. All Kilifi strains had this change that potentially result in loss of recognition 354 by T cells leading to escape from host immune responses [58,59]. Three aa acid changes were 355 observed in VP4 antigenic epitopes in 8-4 (N89D) and 8-3 (Q114P or L114P and N133S) in 356 the Kilifi strains. These have been associated with escape of attachment of the virus to host 357 neutralizing monoclonal antibodies [60]. These aa substitutions were present in both pre- and 358 post-vaccine Kilifi strains, suggesting they were not brought about by vaccine use.

This study had limitations. First, only sequences sampled from hospitalized children were analysed, thus may not conclusively reflect diversity that was in circulation in the entire coastal Kenya population. We only analysed a few genomes across the years. Second, we only recovered near complete genomes. Only 68% coverage was recovered in the VP4 segment.

In conclusion, our study reinforces the significance of genomic sequencing in monitoring the effect of vaccine pressure on circulating RVA strains in Kenya. The Kilifi strains to a large extent clustered based on the vaccination period and were separate from the global strains. Furthermore, conserved amino acid mutations were observed in the VP7 and VP4 antigenic epitopes of the pre- and post-vaccine strains, suggesting that the Rotarix® vaccine did not have a direct impact on the evolution of the circulating strains.

370 Data availability

371 The epidemiological data is available on the VEC dataverse
372 (https://doi.org/10.7910/DVN/P4MRVF).

373 Funding information

This study was funded by the Wellcome Trust (102975, 203077). The authors Timothy Makori, and Charles Agoti were supported by the Initiative to Develop African Research Leaders (IDeAL) through the DELTAS Africa Initiative (DEL-15-003). The DELTAS Africa

Initiative is an independent funding scheme of the African Academy of Sciences (AAS)'s
Alliance for Accelerating Excellence in Science in Africa (AESA) and supported by the New
Partnership for Africa's Development Planning and Coordinating Agency (NEPAD Agency)
with funding from the Wellcome Trust (107769/Z/10/Z) and the UK government. The views
expressed in this publication are those of the authors and not necessarily those of AAS,
NEPAD Agency, Wellcome Trust or the UK government.

383

384 Acknowledgement

We thank all the study participants for their contribution of study samples, their parents/guardians, members of the viral epidemiology and control research group (http://virec-group.org/) and colleagues at the KEMRI Wellcome Trust Research Programme for their useful discussions during the preparation of the manuscript. This paper is published

- 389 with the permission of the Director of KEMRI.
- 390

391 Conflicts of interest

- 392 The authors declare no conflict of interest
- 393

394 References

395 396	1.	WHO Rotavirus Vaccines. Rotavirus vaccines: WHO position paper - July 2021 [Internet]. 2021 [cited 2022 Aug 2]. Available from:
397		https://www.who.int/publications/i/item/WHO-WER9628
398	2.	Varghese T, Kang G, Steele AD. Understanding Rotavirus Vaccine Efficacy
399		and Effectiveness in Countries with High Child Mortality. Vaccines (Basel)
400		[Internet]. 2022 Mar 1 [cited 2022 Aug 2]:10(3). Available from:
401		/pmc/articles/PMC8948967/
402	3.	Tate JE, Burton AH, Boschi-Pinto C, et al. Global, Regional, and National
403		Estimates of Rotavirus Mortality in Children <5 Years of Age. 2000-2013.
404		Clinical Infectious Diseases [Internet], 2016 May 1 [cited 2020 Oct
405		20]:62(suppl 2):S96–105. Available from:
406		https://academic.oup.com/cid/article/62/suppl 2/S96/2478843
407	4.	Troeger C. Khalil IA. Rao PC. et al. Rotavirus Vaccination and the Global
408		Burden of Rotavirus Diarrhea among Children Younger Than 5 Years, JAMA
409		Pediatr [Internet] 2018 Oct 1 [cited 2020 Oct 20]:172(10):958–65 Available
410		from: https://iamanetwork.com/
411	5	Troeger C. Blacker BF Khalil IA et al Estimates of the global regional and
412	5.	national morbidity mortality and actiologies of diarrhoea in 195 countries: a
413		systematic analysis for the Global Burden of Disease Study 2016 Lancet Infect
414		Dis [Internet] 2018 Nov 1 [cited 2020 Oct 20]:18(11):1211–28 Available from:
415		/nmc/articles/PMC6202444/?report=abstract
416	6	Khagavi S. Omore R. Otieno GP et al. Effectiveness of Monovalent Rotavirus
417	0.	Vaccine Against Hospitalization With Acute Rotavirus Gastroenteritis in
418		Kenvan Children 2020 May 23 [cited 2020 Oct 26]:70(11):2298–305
419		Available from: https://academic.oup.com/cid/article/70/11/2298/5536640
420	7	Mwanga MI Owor BE Ochieng IB et al Rotavirus group A genotype
421	<i>,.</i>	circulation patterns across Kenya before and after nationwide vaccine
422		introduction 2010-2018 BMC Infect Dis [Internet] 2020 Jul 13 [cited 2020]
423		Oct $261:20(1):504$ Available from:
424		https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-020-05230-0
425	8.	Gikonyo JN u. Mbatia B. Okanya PW. Obiero GFO. Sang C. Steele D.
426	0.	Nyangao J. Post-vaccine rotavirus genotype distribution in Nairobi County.
427		Kenva International Journal of Infectious Diseases [Internet] 2020 Nov 1 [cited
428		2022 Jun 121:100:434 Available from: /pmc/articles/PMC7670220/
429	9.	Vizzi E. Piñeros OA. Oropeza MD. et al. Human rotavirus strains circulating in
430		Venezuela after vaccine introduction: predominance of G2P[4] and reemergence
431		of G1P[8] Virol J [Internet] 2017 Mar 21 [cited 2022 Aug 2]:14(1):1–14
432		Available from: https://virologyi biomedcentral com/articles/10.1186/s12985-
433		017-0721-9
434	10	Roczo-Farkas S Kirkwood CD Cowley D et al. The Impact of Rotavirus
435	10.	Vaccines on Genotype Diversity: A Comprehensive Analysis of 2 Decades of
436		Australian Surveillance Data I Infect Dis [Internet] 2018 Jul 13 [cited 2022]
437		Aug $21.218(4).546-54$ Available from:
438		https://pubmed.nchi.nlm.nih.gov/29790933/
439	11	Thanh HD Tran VT Lim I Kim W Emergence of Human G2P[4] Rotaviruses
440	•	in the Post-vaccination Era in South Korea. Footprints of Multiple Interspecies
441		Re-assortment Events. Scientific Reports 2018 8-1 [Internet] 2018 Apr 16
442		[cited 2022 May 26]:8(1):1–10 Available from:
443		https://www.nature.com/articles/s41598-018-24511-v
		1

- Zeller M, Rahman M, Heylen E, et al. Rotavirus incidence and genotype distribution before and after national rotavirus vaccine introduction in Belgium.
  Vaccine [Internet]. 2010 Nov 3 [cited 2022 Aug 2];28(47):7507–13. Available from: https://pubmed.ncbi.nlm.nih.gov/20851085/
- 13. Khandoker N, Thongprachum A, Takanashi S, et al. Molecular epidemiology of 448 rotavirus gastroenteritis in Japan during 2014-2015: Characterization of re-449 emerging G2P[4] after rotavirus vaccine introduction. J Med Virol [Internet]. 450 Jun 1 [cited] Aug 2];90(6):1040-6. 451 2018 2022 Available from: 452 https://pubmed.ncbi.nlm.nih.gov/29488230/
- 453 14. Carvalho-Costa FA, de Assis RMS, Fialho AM, et al. The evolving 454 epidemiology of rotavirus A infection in Brazil a decade after the introduction 455 of universal vaccination with Rotarix®. BMC Pediatr [Internet]. 2019 Jan 31 456 2];19(1):1-10. [cited 2022 Aug Available from: 457 https://bmcpediatr.biomedcentral.com/articles/10.1186/s12887-019-1415-9
- 458
  458
  459
  459
  460
  461
  459
  461
  459
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
  461
- 16. Simwaka JC, Mpabalwani EM, Seheri M, et al. Diversity of rotavirus strains 462 circulating in children under five years of age who presented with acute 463 464 gastroenteritis before and after rotavirus vaccine introduction, University Teaching Hospital, Lusaka, Zambia, 2008-2015. Vaccine [Internet]. 2018 Nov 465 466 12 [cited] 2022 Aug 2];36(47):7243-7. Available from: 467 https://pubmed.ncbi.nlm.nih.gov/29907481/
- 468 17. Al-Ayed MSZ, Asaad AM, Qureshi MA, Hawan AA. Epidemiology of group A 469 rotavirus infection after the introduction of monovalent vaccine in the National Immunization Program of Saudi Arabia. J Med Virol [Internet]. 2017 Mar 1 470 471 [cited] 2022 Aug 2];89(3):429–34. Available from: https://pubmed.ncbi.nlm.nih.gov/27531633/ 472
- Than VT, Jeong S, Kim W. A systematic review of genetic diversity of human rotavirus circulating in South Korea. Infect Genet Evol [Internet]. 2014 Dec [cited 2018 Mar 16];28:462–9. Available from: http://linkinghub.elsevier.com/retrieve/pii/S1567134814003086
- 477 19. Ghosh S, Kobayashi N. Whole-genomic analysis of rotavirus strains: Current status and future prospects [Internet]. Vol. 6, Future Microbiology. Future Medicine Ltd London, UK ; 2011 [cited 2020 Oct 26]. p. 1049–65. Available from: www.futuremedicine.com
- 48120.Matthijnssens J, Ciarlet M, Rahman M, et al. Recommendations for the<br/>classification of group A rotaviruses using all 11 genomic RNA segments. Arch<br/>Virol [Internet]. 2008 [cited 2018 Jan 5];153(8):1621–9. Available from:<br/>http://link.springer.com/10.1007/s00705-008-0155-1
- Doan YH, Nakagomi T, Agbemabiese CA, Nakagomi O. Changes in the 485 21. 486 distribution of lineage constellations of G2P[4] Rotavirus A strains detected in 487 Japan over 32years (1980-2011). Infection, Genetics and Evolution [Internet]. [cited 2020 Oct 27]:34:423–33. 488 2015 Aug 1 Available from: 489 https://pubmed.ncbi.nlm.nih.gov/26026594/
- 490 22. Agbemabiese CA, Nakagomi T, Doan YH, Do LP, Damanka S, Armah GE,
  491 Nakagomi O. Genomic constellation and evolution of Ghanaian G2P[4]
  492 rotavirus strains from a global perspective. Infection, Genetics and Evolution.
  493 2016 Nov 1;45:122–31.

494	23.	Giammanco GM, Bonura F, Zeller M, et al. Evolution of DS-1-like human
495		G2P[4] rotaviruses assessed by complete genome analyses. Journal of General
496		Virology [Internet]. 2014 Jan 1 [cited 2020 Oct 27];95(PART 1):91-109.
497		Available from:
498		https://www.microbiologyresearch.org/content/journal/jgv/10.1099/vir.0.05678
499		8-0
500	24.	Mwangi PN, Page NA, Seheri ML, et al. Evolutionary changes between pre-
501		and post-vaccine South African group A G2P[4] rotavirus strains, 2003–2017.
502		Microb Genom [Internet]. 2022 Apr 21 [cited 2022 May 26];8(4):000809.
503		Available from:
504		https://www.microbiologyresearch.org/content/journal/mgen/10.1099/mgen.0.0
505		00809
506	25.	Donato CM, Pingault N, Demosthenous E, Roczo-farkas S, Bines JE.
507		Characterisation of a G2P[4] Rotavirus Outbreak in Western Australia,
508		Predominantly Impacting Aboriginal Children. Pathogens 2021, Vol 10, Page
509		350 [Internet]. 2021 Mar 16 [cited 2022 May 26];10(3):350. Available from:
510		https://www.mdpi.com/2076-0817/10/3/350/htm
511	26.	Donato CM, Zhang ZA, Donker NC, Kirkwood CD. Characterization of G2P[4]
512		rotavirus strains associated with increased detection in Australian states using
513		the RotaTeg® vaccine during the 2010-2011 surveillance period. Infect Genet
514		Evol [Internet]. 2014 Dec 1 [cited 2018 Mar 16];28:398–412. Available from:
515		http://linkinghub.elsevier.com/retrieve/pii/S1567134814001890
516	27.	Aida S, Nahar S, Paul SK, et al. Whole genomic analysis of G2P[4] human
517		Rotaviruses in Mymensingh, north-central Bangladesh, Helivon, 2016 Sep
518		1:2(9):e00168.
519	28.	Gómez MM, Carvalho-Costa FA, Volotão E de M, et al. Prevalence and
520		genomic characterization of G2P[4] group A rotavirus strains during
521		monovalent vaccine introduction in Brazil. Infect Genet Evol [Internet]. 2014
522		Dec [cited 2018 Mar 16];28:486–94. Available from:
523		http://linkinghub.elsevier.com/retrieve/pii/S1567134814003402
524	29	Scott IAG Bauni E Moisi IC et al Profile: The Kilifi Health and Demographic
525	<i></i> .	Scott JAO, Daum L, Moisi JC, et al. Home. The Kinn Heatin and Demographic
	27.	Surveillance System (KHDSS). Int J Epidemiol [Internet]. 2012 Jun [cited 2022]
526	27.	Surveillance System (KHDSS). Int J Epidemiol [Internet]. 2012 Jun [cited 2022 Aug 3];41(3):650–7. Available from:
526 527	27.	Surveillance System (KHDSS). Int J Epidemiol [Internet]. 2012 Jun [cited 2022 Aug 3];41(3):650–7. Available from: https://pubmed.ncbi.nlm.nih.gov/22544844/
526 527 528	30.	Surveillance System (KHDSS). Int J Epidemiol [Internet]. 2012 Jun [cited 2022 Aug 3];41(3):650–7. Available from: https://pubmed.ncbi.nlm.nih.gov/22544844/ Otieno GP, Bottomley C, Khagayi S, et al. Impact of the introduction of
526 527 528 529	30.	Surveillance System (KHDSS). Int J Epidemiol [Internet]. 2012 Jun [cited 2022 Aug 3];41(3):650–7. Available from: https://pubmed.ncbi.nlm.nih.gov/22544844/ Otieno GP, Bottomley C, Khagayi S, et al. Impact of the introduction of rotavirus vaccine on hospital admissions for diarrhea among children in Kenya:
526 527 528 529 530	30.	Surveillance System (KHDSS). Int J Epidemiol [Internet]. 2012 Jun [cited 2022 Aug 3];41(3):650–7. Available from: https://pubmed.ncbi.nlm.nih.gov/22544844/ Otieno GP, Bottomley C, Khagayi S, et al. Impact of the introduction of rotavirus vaccine on hospital admissions for diarrhea among children in Kenya: A controlled interrupted time-series analysis. Clinical Infectious Diseases. 2020
526 527 528 529 530 531	30.	Surveillance System (KHDSS). Int J Epidemiol [Internet]. 2012 Jun [cited 2022 Aug 3];41(3):650–7. Available from: https://pubmed.ncbi.nlm.nih.gov/22544844/ Otieno GP, Bottomley C, Khagayi S, et al. Impact of the introduction of rotavirus vaccine on hospital admissions for diarrhea among children in Kenya: A controlled interrupted time-series analysis. Clinical Infectious Diseases. 2020 Jun 1;70(11):2306–13.
526 527 528 529 530 531 532	30. 31.	Surveillance System (KHDSS). Int J Epidemiol [Internet]. 2012 Jun [cited 2022 Aug 3];41(3):650–7. Available from: https://pubmed.ncbi.nlm.nih.gov/22544844/ Otieno GP, Bottomley C, Khagayi S, et al. Impact of the introduction of rotavirus vaccine on hospital admissions for diarrhea among children in Kenya: A controlled interrupted time-series analysis. Clinical Infectious Diseases. 2020 Jun 1;70(11):2306–13. Pickett BE, Sadat EL, Zhang Y, et al. ViPR: an open bioinformatics database
526 527 528 529 530 531 532 533	<ul><li>30.</li><li>31.</li></ul>	Surveillance System (KHDSS). Int J Epidemiol [Internet]. 2012 Jun [cited 2022 Aug 3];41(3):650–7. Available from: https://pubmed.ncbi.nlm.nih.gov/22544844/ Otieno GP, Bottomley C, Khagayi S, et al. Impact of the introduction of rotavirus vaccine on hospital admissions for diarrhea among children in Kenya: A controlled interrupted time-series analysis. Clinical Infectious Diseases. 2020 Jun 1;70(11):2306–13. Pickett BE, Sadat EL, Zhang Y, et al. ViPR: an open bioinformatics database and analysis resource for virology research. Nucleic Acids Res [Internet]. 2012
526 527 528 529 530 531 532 533 533	<ul><li>30.</li><li>31.</li></ul>	Surveillance System (KHDSS). Int J Epidemiol [Internet]. 2012 Jun [cited 2022 Aug 3];41(3):650–7. Available from: https://pubmed.ncbi.nlm.nih.gov/22544844/ Otieno GP, Bottomley C, Khagayi S, et al. Impact of the introduction of rotavirus vaccine on hospital admissions for diarrhea among children in Kenya: A controlled interrupted time-series analysis. Clinical Infectious Diseases. 2020 Jun 1;70(11):2306–13. Pickett BE, Sadat EL, Zhang Y, et al. ViPR: an open bioinformatics database and analysis resource for virology research. Nucleic Acids Res [Internet]. 2012 Jan [cited 2021 Oct 27];40(Database issue):D593. Available from:
526 527 528 529 530 531 532 533 533 534 535	30. 31.	Surveillance System (KHDSS). Int J Epidemiol [Internet]. 2012 Jun [cited 2022 Aug 3];41(3):650–7. Available from: https://pubmed.ncbi.nlm.nih.gov/22544844/ Otieno GP, Bottomley C, Khagayi S, et al. Impact of the introduction of rotavirus vaccine on hospital admissions for diarrhea among children in Kenya: A controlled interrupted time-series analysis. Clinical Infectious Diseases. 2020 Jun 1;70(11):2306–13. Pickett BE, Sadat EL, Zhang Y, et al. ViPR: an open bioinformatics database and analysis resource for virology research. Nucleic Acids Res [Internet]. 2012 Jan [cited 2021 Oct 27];40(Database issue):D593. Available from: /pmc/articles/PMC3245011/
526 527 528 529 530 531 532 533 534 535 536	<ul><li>30.</li><li>31.</li><li>32.</li></ul>	Surveillance System (KHDSS). Int J Epidemiol [Internet]. 2012 Jun [cited 2022 Aug 3];41(3):650–7. Available from: https://pubmed.ncbi.nlm.nih.gov/22544844/ Otieno GP, Bottomley C, Khagayi S, et al. Impact of the introduction of rotavirus vaccine on hospital admissions for diarrhea among children in Kenya: A controlled interrupted time-series analysis. Clinical Infectious Diseases. 2020 Jun 1;70(11):2306–13. Pickett BE, Sadat EL, Zhang Y, et al. ViPR: an open bioinformatics database and analysis resource for virology research. Nucleic Acids Res [Internet]. 2012 Jan [cited 2021 Oct 27];40(Database issue):D593. Available from: /pmc/articles/PMC3245011/ Phan MVT, Anh PH, Cuong N van, et al. Unbiased whole-genome deep
526 527 528 529 530 531 532 533 534 535 536 537	<ul><li>30.</li><li>31.</li><li>32.</li></ul>	Surveillance System (KHDSS). Int J Epidemiol [Internet]. 2012 Jun [cited 2022 Aug 3];41(3):650–7. Available from: https://pubmed.ncbi.nlm.nih.gov/22544844/ Otieno GP, Bottomley C, Khagayi S, et al. Impact of the introduction of rotavirus vaccine on hospital admissions for diarrhea among children in Kenya: A controlled interrupted time-series analysis. Clinical Infectious Diseases. 2020 Jun 1;70(11):2306–13. Pickett BE, Sadat EL, Zhang Y, et al. ViPR: an open bioinformatics database and analysis resource for virology research. Nucleic Acids Res [Internet]. 2012 Jan [cited 2021 Oct 27];40(Database issue):D593. Available from: /pmc/articles/PMC3245011/ Phan MVT, Anh PH, Cuong N van, et al. Unbiased whole-genome deep sequencing of human and porcine stool samples reveals circulation of multiple
526 527 528 529 530 531 532 533 534 535 536 536 537 538	<ul><li>30.</li><li>31.</li><li>32.</li></ul>	Sect 3AG, Baun E, Molsi 3C, et al. Home. The Rhin Health and Demographic Surveillance System (KHDSS). Int J Epidemiol [Internet]. 2012 Jun [cited 2022 Aug 3];41(3):650–7. Available from: https://pubmed.ncbi.nlm.nih.gov/22544844/ Otieno GP, Bottomley C, Khagayi S, et al. Impact of the introduction of rotavirus vaccine on hospital admissions for diarrhea among children in Kenya: A controlled interrupted time-series analysis. Clinical Infectious Diseases. 2020 Jun 1;70(11):2306–13. Pickett BE, Sadat EL, Zhang Y, et al. ViPR: an open bioinformatics database and analysis resource for virology research. Nucleic Acids Res [Internet]. 2012 Jan [cited 2021 Oct 27];40(Database issue):D593. Available from: /pmc/articles/PMC3245011/ Phan MVT, Anh PH, Cuong N van, et al. Unbiased whole-genome deep sequencing of human and porcine stool samples reveals circulation of multiple groups of rotaviruses and a putative zoonotic infection. Virus Evol [Internet].
526 527 528 529 530 531 532 533 534 535 536 537 538 539	<ul><li>30.</li><li>31.</li><li>32.</li></ul>	Sect 3AG, Baun E, Molsi 3C, et al. Home. The Rhin Health and Demographic Surveillance System (KHDSS). Int J Epidemiol [Internet]. 2012 Jun [cited 2022 Aug 3];41(3):650–7. Available from: https://pubmed.ncbi.nlm.nih.gov/22544844/ Otieno GP, Bottomley C, Khagayi S, et al. Impact of the introduction of rotavirus vaccine on hospital admissions for diarrhea among children in Kenya: A controlled interrupted time-series analysis. Clinical Infectious Diseases. 2020 Jun 1;70(11):2306–13. Pickett BE, Sadat EL, Zhang Y, et al. ViPR: an open bioinformatics database and analysis resource for virology research. Nucleic Acids Res [Internet]. 2012 Jan [cited 2021 Oct 27];40(Database issue):D593. Available from: /pmc/articles/PMC3245011/ Phan MVT, Anh PH, Cuong N van, et al. Unbiased whole-genome deep sequencing of human and porcine stool samples reveals circulation of multiple groups of rotaviruses and a putative zoonotic infection. Virus Evol [Internet]. 2016 Jul [cited 2018 Mar 16];2(2):vew027. Available from:
526 527 528 529 530 531 532 533 534 535 536 537 538 539 540	<ul><li>30.</li><li>31.</li><li>32.</li></ul>	Scott 3AO, Badin E, Wolsi JC, et al. 110file. The Kinn Health and Demographic Surveillance System (KHDSS). Int J Epidemiol [Internet]. 2012 Jun [cited 2022 Aug 3];41(3):650–7. Available from: https://pubmed.ncbi.nlm.nih.gov/22544844/ Otieno GP, Bottomley C, Khagayi S, et al. Impact of the introduction of rotavirus vaccine on hospital admissions for diarrhea among children in Kenya: A controlled interrupted time-series analysis. Clinical Infectious Diseases. 2020 Jun 1;70(11):2306–13. Pickett BE, Sadat EL, Zhang Y, et al. ViPR: an open bioinformatics database and analysis resource for virology research. Nucleic Acids Res [Internet]. 2012 Jan [cited 2021 Oct 27];40(Database issue):D593. Available from: /pmc/articles/PMC3245011/ Phan MVT, Anh PH, Cuong N van, et al. Unbiased whole-genome deep sequencing of human and porcine stool samples reveals circulation of multiple groups of rotaviruses and a putative zoonotic infection. Virus Evol [Internet]. 2016 Jul [cited 2018 Mar 16];2(2):vew027. Available from: https://academic.oup.com/ve/article-lookup/doi/10.1093/ve/vew027
526 527 528 529 530 531 532 533 534 535 536 537 538 539 540 541	<ul> <li>30.</li> <li>31.</li> <li>32.</li> <li>33.</li> </ul>	Scott 3/KG, Baum E, Molsi 3C, et al. Home. The Kinn Heatin and Demographic Surveillance System (KHDSS). Int J Epidemiol [Internet]. 2012 Jun [cited 2022 Aug 3];41(3):650–7. Available from: https://pubmed.ncbi.nlm.nih.gov/22544844/ Otieno GP, Bottomley C, Khagayi S, et al. Impact of the introduction of rotavirus vaccine on hospital admissions for diarrhea among children in Kenya: A controlled interrupted time-series analysis. Clinical Infectious Diseases. 2020 Jun 1;70(11):2306–13. Pickett BE, Sadat EL, Zhang Y, et al. ViPR: an open bioinformatics database and analysis resource for virology research. Nucleic Acids Res [Internet]. 2012 Jan [cited 2021 Oct 27];40(Database issue):D593. Available from: /pmc/articles/PMC3245011/ Phan MVT, Anh PH, Cuong N van, et al. Unbiased whole-genome deep sequencing of human and porcine stool samples reveals circulation of multiple groups of rotaviruses and a putative zoonotic infection. Virus Evol [Internet]. 2016 Jul [cited 2018 Mar 16];2(2):vew027. Available from: https://academic.oup.com/ve/article-lookup/doi/10.1093/ve/vew027 Fujii Y, Shimoike T, Takagi H, Murakami K, Todaka-Takai R, Park Y,

<b>E</b> 40		
543		based on reverse transcription polymerase chain reaction. Microbiol Immunol. $2012$ S = $5(0)$ (20, 9)
544	24	2012  Sep;56(9):630-8.
545	34.	Magagula NB, Esona MD, Nyaga MM, et al. whole Genome Analyses of
546		GIP[8] Rotavirus Strains From Vaccinated and Non-Vaccinated South African
547		Children Presenting With Diarrhea HHS Public Access. J Med Virol.
548	~-	2015;87(1):79–101.
549	35.	Boom R, Sol CJ, Salimans MM, Jansen CL, Dillen PMW, Noordaa J van der.
550		Rapid and simple method for purification of nucleic acids. J Clin Microbiol
551		[Internet]. 1990 [cited 2021 Oct 27];28(3):495. Available from:
552		/pmc/articles/PMC269651/?report=abstract
553	36.	Endoh D, Mizutani T, Kirisawa R, et al. Species-independent detection of RNA
554		virus by representational difference analysis using non-ribosomal
555		hexanucleotides for reverse transcription. Nucleic Acids Res [Internet]. 2005
556		[cited 2022 Aug 3];33(6):e65. Available from: /pmc/articles/PMC1074749/
557	37.	Liu J, Gratz J, Amour C, et al. Optimization of quantitative PCR methods for
558		enteropathogen detection. PLoS One. 2016 Jun 1;11(6).
559	38.	Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina
560		sequence data. Bioinformatics [Internet]. 2014 Aug 1 [cited 2021 Oct
561		27];30(15):2114. Available from: /pmc/articles/PMC4103590/
562	39.	Bankevich A, Nurk S, Antipov D, et al. SPAdes: A New Genome Assembly
563		Algorithm and Its Applications to Single-Cell Sequencing. Journal of
564		Computational Biology [Internet]. 2012 May 1 [cited 2018 Jan 5];19(5).
565		Available from: http://www.ncbi.nlm.nih.gov/pubmed/22506599
566	40.	USEARCH algorithm [Internet]. [cited 2022 Sep 28]. Available from:
567		https://www.drive5.com/usearch/manual/usearch_algo.html
568	41.	Cotten M, Oude Munnink B, Canuti M, Deijs M, Watson SJ, Kellam P, van der
569		Hoek L. Full Genome Virus Detection in Fecal Samples Using Sensitive
570		Nucleic Acid Preparation, Deep Sequencing, and a Novel Iterative Sequence
571		Classification Algorithm. PLoS One [Internet]. 2014 Apr 2 [cited 2022 Sep
572		28];9(4):e93269. Available from:
573		https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0093269
574	42.	Sequencher DNA Sequence Analysis Software from Gene Codes Corporation
575		[Internet]. [cited 2022 Sep 28]. Available from: http://www.genecodes.com/
576	43.	Gurevich A. Saveliev V. Vvahhi N. Tesler G. OUAST: quality assessment tool
577		for genome assemblies. Bioinformatics [Internet]. 2013 Apr 15 [cited 2021 Oct
578		27];29(8):1072. Available from: /pmc/articles/PMC3624806/
579	44.	Carver T. Harris SR. Berriman M. Parkhill J. McOuillan JA. Artemis: an
580		integrated platform for visualization and analysis of high-throughput sequence-
581		based experimental data. Bioinformatics [Internet]. 2012 Feb [cited 2021 Oct
582		271:28(4):464. Available from: /pmc/articles/PMC3278759/
583	45.	Katoh K. Misawa K. Kuma K. Miyata T. MAFFT: a novel method for rapid
584		multiple sequence alignment based on fast Fourier transform Nucleic Acids Res
585		[Internet] 2002 Jul 15 [cited 2021 Oct 28]:30(14):3059 Available from:
586		/nmc/articles/PMC135756/
587	46	Minh BO Schmidt HA Chernomor O Schrempf D Woodhams MD von
588	10.	Haeseler A Lanfear R IO-TREE ? New Models and Efficient Methods for
589		Phylogenetic Inference in the Genomic Fra Mol Riol Fvol [Internet] 2020 May
590		1 [cited $2021$ Oct $28$ ]· $37(5)$ · $1530_4$ Available from:
591		https://academic.oup.com/mbe/article/ $37/5/1530/5721363$
		maps, rueadonne.oup.com/mor/attrefe/3/13/1330/3/21303

- 592 47. Subha K, Minh BQ, Wong TKF, von Haeseler A, Jermiin LS. ModelFinder:
  593 Fast model selection for accurate phylogenetic estimates. Nat Methods. 2017
  594 May 30;14(6):587–9.
- 595 48. Hoang DT, Chernomor O, Haeseler A von, Minh BQ, Vinh LS. UFBoot2: Improving the Ultrafast Bootstrap Approximation. Mol Biol Evol [Internet]. 596 597 Feb [cited 2021 2018 1 Oct 28];35(2):518. Available from: /pmc/articles/PMC5850222/ 598
- 599 49. Statistical software for data science | Stata [Internet]. [cited 2022 Oct 13].
  600 Available from: https://www.stata.com/
- 60150.Liu L. Fields Virology, 6th Edition. Clinical Infectious Diseases [Internet]. 2014602Aug 15 [cited 2022 Sep 15];59(4):613–613. Available from:603https://academic.oup.com/cid/article/59/4/613/2895607
- 60451.Aoki ST, Settembre EC, Trask SD, Greenberg HB, Harrison SC, Dormitzer PR.605Structure of rotavirus outer-layer protein VP7 bound with a neutralizing Fab.606Science [Internet]. 2009 Jun 6 [cited 2022 Aug 11];324(5933):1444. Available607from: /pmc/articles/PMC2995306/
- 52. Dormitzer PR, Sun ZYJ, Wagner G, Harrison SC. The rhesus rotavirus VP4
  sialic acid binding domain has a galectin fold with a novel carbohydrate binding
  site. EMBO Journal. 2002 Mar 1;21(5):885–97.
- 53. Dennis AF, McDonald SM, Payne DC, et al. Molecular epidemiology of
  contemporary G2P[4] human rotaviruses cocirculating in a single U.S.
  community: footprints of a globally transitioning genotype. J Virol [Internet].
  2014 Apr 1 [cited 2018 Mar 15];88(7):3789–801. Available from: http://jvi.asm.org/cgi/doi/10.1128/JVI.03516-13
- 61654.Rasebotsa S, Mwangi PN, Mogotsi MT, et al. Whole genome and in-silico617analyses of G1P[8] rotavirus strains from pre- and post-vaccination periods in618Rwanda. Scientific Reports 2020 10:1 [Internet]. 2020 Aug 10 [cited 2022 Aug61915];10(1):1–22. Available from: https://www.nature.com/articles/s41598-020-62069973-1
- 55. Zeller M, Donato C, Trovão NS, et al. Genome-Wide Evolutionary Analyses of
  G1P[8] Strains Isolated Before and After Rotavirus Vaccine Introduction.
  Genome Biol Evol [Internet]. 2015 Sep 1 [cited 2022 Aug 15];7(9):2473–83.
  Available from: https://pubmed.ncbi.nlm.nih.gov/26254487/
- 62556.Munlela B, João ED, Donato CM, et al. Whole Genome Characterization and626Evolutionary Analysis of G1P[8] Rotavirus A Strains during the Pre- and Post-627Vaccine Periods in Mozambique (2012–2017). Pathogens [Internet]. 2020 Dec 1628[cited 2022 Aug 19];9(12):1–19. Available from: /pmc/articles/PMC7762294/
- 57. Dyall-Smith ML, Lazdins I, Tregear GW, Holmes IH. Location of the major
  antigenic sites involved in rotavirus serotype-specific neutralization. Proc Natl
  Acad Sci U S A [Internet]. 1986 [cited 2022 Jun 3];83(10):3465–8. Available
  from: https://pubmed.ncbi.nlm.nih.gov/2422651/
- 58. Morozova O v., Sashina TA, Fomina SG, Novikova NA. Comparative
  characteristics of the VP7 and VP4 antigenic epitopes of the rotaviruses
  circulating in Russia (Nizhny Novgorod) and the Rotarix and RotaTeq vaccines.
  Arch Virol. 2015 Jul 15;160(7):1693–703.
- 637 59. Wei J, Li J, Zhang X, Tang Y, Wang J, Wu Y. A naturally processed epitope on rotavirus VP7 glycoprotein recognized by HLA-A2.1-restricted cytotoxic CD8+ T cells. Viral Immunol. 2009 Jun 1;22(3):189–94.
- 640 60. Monnier N, Higo-Moriguchi K, Sun Z-YJ, Prasad BVV, Taniguchi K,
  641 Dormitzer PR. High-Resolution Molecular and Antigen Structure of the VP8\*

642	Core of	a Sialio	c Acid-In	depender	nt Huma	an Rotavirus Strain	. J Virol [In	ternet].
643	2006	Feb	[cited	2022	Aug	17];80(3):1513.	Available	from:
644	/pmc/art	ticles/PN	MC13469	36/				

645

646

647



648

medRxiv preprint doi: https://doi.org/10.1101/2022.10.21.22281210; this version posted October 24, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .



655

656

657

Fig. 2: Phylogenetic reconstruction of the 63 Kilifi G2P[4] sequences against a backdrop of 350 global sequences for the VP7 and VP4 RVA genome segments using maximum likelihood (ML) methods. The Kilifi sequences are colored by the period of sample collection (either before or after vaccine introduction in Kenya). For all the global sequences, more than 80% of the coding sequence (CDS) region was considered for analysis. For the Kilifi sequences, >80% CDS were used for the VP7 and 68% for the VP4 segment. The study sequences classified to the lineages indicated in each phylogenetic tree.



665

666

Fig. 3: Temporal pattern of the G2 and P[4] lineages observed in Kilifi and globally. (A)

Temporal pattern of the Kilifi G2 lineages from 2012 to 2018 and temporal pattern of the

global G2 lineages from 2010 to 2018. (C) Temporal pattern of the Kilifi P[4] lineages from
2012 to 2018 and temporal pattern of the global P[4] lineages from 2010 to 2018.



Fig. 4: A sequence logo showing the amino changes observed in known antigenic epitopes of

G2 and P[4] proteins in the Kilifi G2P[4] relative to the ancestral DS-1 strain. The changes inamino acids are shown in different color schemes.

- ----

# 693 Supplementary Figure Legend

Fig. S1: Phylogenetic reconstruction of the 63 Kilifi G2P[4] sequences against a backdrop of 350 global sequences for the VP6, VP1, VP2, VP3, NSP1, NSP2, NSP3, NSP4, and NSP5 RVA genome segments using maximum likelihood (ML) methods. The Kilifi sequences are colored by the period of sample collection (either before or after vaccine introduction in Kenya). For the Kilifi and all the global sequences, more than 80% of the coding sequence (CDS) region was considered for analysis. The study sequences classified to the lineages indicated in each phylogenetic tree.

Characteristics	RVA	Successfully	All	non-G2P [4]	All G2P[4] vs	
	Positives	Sequenced	G2P[4]	(%)	non-G2P[4] P-	
	(%)	G2P[4]	(%)		value	
		(%)				
Total cases	429	63 (14.7)	87 (20.3)	342 (79.7)		
Vaccine period					0.039	
Pre-vaccine	215 (49.9)	33 (52.4)	35 (40.2)	180 (52.6)		
Post-vaccine	214 (50.1)	30 (47.6)	52 (59.8)	162 (47.4)		
Age (in months)					0.944	
Mean (SD)	14.9 (13.1)	17.6 (16.4)	16.9 (15.4)	14.4 (12.4)		
Median (IQR)	11.7 (8.3-	11.2 (8.6-	10.6 (8.4-	12.2 (8.3-		
	17.9)	20.7)	19.7)	16.8)		
Age group (in months)					0.092	
0-11m	216 (50.4)	33 (52.4)	47 (54.0)	216 (50.4)		
12–23m	169 (39.4)	20 (31.2)	26 (29.9)	143 (41.8)		
24– 59m	35 (8.2)	7 (11.1)	11 (12.6)	24 (7.0)		
>=60 m	9 (2.1)	3 (4.8)	3 (3.5)	6 (1.7)		
Gender					0.789	
Male	251 (51.5)	37 (58.7)	52 (59.7)	199 (58.2)		
Vaccination					0.129	
status						
Vaccinated	88 (20.6)	14 (22.2)	22 (25.6)	66 (19.4)		
Not vaccinated	215 (50.4)	33 (52.4)	35 (40.7)	180 (52.8)		
Unknown	124 (29.0)	16 (25.4)	29 (33.7)	95 (27.9)		
<sup>1</sup> Full vaccination	79 (18.4)	13 (20.6)	21 (24.1)	58 (17.0)	0.256	

Table 1: Baseline demographic characteristics of the children that were rotavirus positive and those found to be G2P[4] infected during the study period (2012 to 2018)

<sup>&</sup>lt;sup>1</sup> Full vaccination implies that the participants received two doses of the Rotarix vaccine as recommended by WHO

Genome	Percentage	Percentage
Genome	nucleotide	amino
segment	nucleonde	
	similarity	acid
		similarity
VP4	94.3-100	96.8-100
VP7	94.3-100	96.3-100
VP6	94.0-100	96.0-100
VP1	93.9-100	98.0-100
VP2	97.2-100	99.2-100
VP3	87.1-100	92.1-100
NSP1	95.7-100	96.0-100
NSP2	97.3-100	97.5-100
NSP3	97.1-100	98.4-100
NSP4	85.0-100	91.5-100
NSP5	94.5-100	94.5-100

T 11 0 D	1 (* 1 1	· ·	· 1 · 1 /·/	C (1	17:1.6. 6		· ·
I anie 7º Percentage	nucleofide and	amino aci	id identity '	for the	K 111T1 (	T/PI41	strains
1 abic 2. 1 cicontage	nucleonac and	a uninto uo	iu iuciitity.	ior the	I XIIIII (	J <u> </u>	Suamo
0			2				